Your browser doesn't support javascript.
loading
Pharmacoepidemiology evaluation of bumetanide as a potential candidate for drug repurposing for Alzheimer's disease.
Morales, Jasmine; Gabriel, Nico; Natarajan, Loki; LaCroix, Andrea Z; Shadyab, Aladdin H; Xu, Ronghui; Silverman, James; Feldman, Howard H; Hernandez, Inmaculada.
Afiliación
  • Morales J; Herbert Wertheim School of Public Health & Human Longevity Science, University of California, San Diego, La Jolla, California, USA.
  • Gabriel N; Division of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California, USA.
  • Natarajan L; Herbert Wertheim School of Public Health & Human Longevity Science, University of California, San Diego, La Jolla, California, USA.
  • LaCroix AZ; Herbert Wertheim School of Public Health & Human Longevity Science, University of California, San Diego, La Jolla, California, USA.
  • Shadyab AH; Herbert Wertheim School of Public Health & Human Longevity Science, University of California, San Diego, La Jolla, California, USA.
  • Xu R; Division of Geriatrics, Gerontology, and Palliative Care, Department of Medicine, University of California, San Diego, La Jolla, California, USA.
  • Silverman J; Herbert Wertheim School of Public Health & Human Longevity Science, University of California, San Diego, La Jolla, California, USA.
  • Feldman HH; Department of Mathematics, University of California, San Diego, La Jolla, California, USA.
  • Hernandez I; Halicioglu Data Science Institute, University of California, San Diego, La Jolla, California, USA.
Alzheimers Dement ; 20(8): 5236-5246, 2024 08.
Article en En | MEDLINE | ID: mdl-39030734
ABSTRACT

INTRODUCTION:

Bumetanide, a loop diuretic, was identified as a candidate drug for repurposing for Alzheimer's disease (AD) based on its effects on transcriptomic apolipoprotein E signatures. Cross-sectional analyses of electronic health records suggest that bumetanide is associated with decreased prevalence of AD; however, temporality between bumetanide exposure and AD development has not been established.

METHODS:

We evaluated Medicare claims data using Cox proportional hazards regression to evaluate the association between time-dependent use of bumetanide and time to first AD diagnosis while controlling for patient characteristics. Multiple sensitivity analyses were conducted to test the robustness of the findings.

RESULTS:

We sampled 833,561 Medicare beneficiaries, 60.8% female, with mean (standard deviation) age of 70.4 (12). Bumetanide use was not significantly associated with AD risk (hazard ratio 1.05; 95% confidence interval, 0.99-1.10).

DISCUSSION:

Using a nationwide dataset and a retrospective cohort study design, we were not able to identify a time-dependent effect of bumetanide lowering AD risk. HIGHLIGHTS Bumetanide was identified as a candidate for repurposing for Alzheimer's disease (AD). We evaluated the association between bumetanide use and risk of AD. We used Medicare data and accounted for duration of bumetanide use. Bumetanide use was not significantly associated with risk of AD.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Bumetanida / Medicare / Farmacoepidemiología / Reposicionamiento de Medicamentos / Enfermedad de Alzheimer Límite: Aged / Aged80 / Female / Humans / Male País/Región como asunto: America do norte Idioma: En Revista: Alzheimers Dement Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Bumetanida / Medicare / Farmacoepidemiología / Reposicionamiento de Medicamentos / Enfermedad de Alzheimer Límite: Aged / Aged80 / Female / Humans / Male País/Región como asunto: America do norte Idioma: En Revista: Alzheimers Dement Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos